Home › Therapeutic areas › Immunology › Ulcerative Colitis

Ulcerative Colitis (8 companies)

Companies with an active program in Ulcerative Colitis.

Ticker Company Therapeutic areas Programs Lead stage Mkt cap Programs
ABVX Abivax Immunology 1 Phase 3 $7.19B 2
EVMN Evommune DermatologyImmunology+1 1 Phase 2 $290M 6
PTN Palatin Technologies ImmunologyMetabolic+1 1 Phase 3 $9.5M 5
PALI Palisade Bio Immunology 1 Phase 2 $181M 3
PTGX Protagonist Therapeutics DermatologyHematology+2 Rare 1 Approved $8.14B 12
SYRE Spyre Therapeutics DermatologyImmunology Rare 6 Phase 2 $8.91B 10
VNDA Vanda Pharmaceuticals CardiovascularDermatology+6 Rare 1 Approved $230M 27
XNCR Xencor ImmunologyNeurology+1 Rare 2 Approved $2.59B 28